CCRM Australia aims to build upon existing efforts to overcome industry challenges with established CCRM services and experience.

By engaging local regenerative medicine (RM) companies to be part of the CCRM industry consortium, we aim to raise the rates of success for collaboration and innovation within Australia and promote more opportunities to link Australian companies to international networks and expertise.

The industry consortium sponsorship and engagement model provides sponsors with increased access to CCRM expertise, market knowledge and networks of key opinion leaders.

Australian companies that access the network through CCRM Australia will also benefit from specialised local support provided by the Regenerative Medicine Industry Interface (RMI2) a consortium of local regenerative medicine industry participants, key academic and dedicated service providers and peak bodies. The consortium provides subsidised industry-focused research programs and initiatives that support the research and business objectives of the local regenerative medicine companies.

Joining the industry consortium offers industry members unparalleled opportunities and access to the global regenerative medicine network. The current industry consortium includes large multinationals, small-medium enterprises (SME) and emerging biotechnology companies in key sectors of regenerative medicine including, pharmaceutical, devices, reagents, tools, biomaterials and cell therapies.